Logo Logo
Switch Language to German

Stoeckelhuber, Markus, Scherer, Max, Peschel, Oliver, Leibold, Edgar, Bracher, Franz, Scherer, Gerhard and Pluym, Nikola (2020): Human metabolism and urinary excretion kinetics of the UV filter Uvinul A plus (R) after a single oral or dermal dosage. In: International Journal of Hygiene and Environmental Health, Vol. 227, 113509

Full text not available from 'Open Access LMU'.


Hexyl 2-[4-(diethylamino)-2-hydroxybenzoyl]benzoate, better known under its trading name Uvinul A plus (R) is a UV filter mainly used in sunscreens, but also present in other cosmetic products with a maximum concentration of 10% (w/w) according to the EU directive. In this study we investigated the human metabolism after a single oral and a single dermal dose of Uvinul A plus (R), respectively. Samples collected within 72 h of administration were analyzed with a newly developed UHPLC-MS/MS method. Results of the study revealed three major urinary metabolites, namely 2-(4-amino-2-hydroxybenzoyl)benzoic acid (AHB), 2-(4-(ethylamino)-2-hydroxybenzoyl)benzoic acid (EHB) and 2-(4-(diethylamino)-2-hydroxybenzoyl)benzoic acid (DHB), representing 52% of the administered oral dose. The three major metabolites are further converted into four minor metabolites with an additional hydroxyl group in the aniline moiety. Toxicokinetic parameters (amount excreted, t(max), elimination constant and half-life t(1/2)) and conversion factors were determined for the three major metabolites. The conversion factors were used to estimate the mean daily exposure to Uvinul A plus (R) in spot urine samples from 58 volunteers not intentionally exposed to Uvinul A plus (R) derived from a pilot study. The three major metabolites were quantifiable in 26% of the samples. In 35% of the samples, at least one major metabolite could be quantified. The daily systemic exposure to Uvinul A plus (R) was estimated to approximately 8.1-9.3 mu g/d by applying the combined conversion factor for all three major metabolites. In conclusion, a very low systemic exposure to DHHB was observed with regard to the no observed adverse effect level (NOAEL) as an established threshold for chronic uptake.

Actions (login required)

View Item View Item